Guggenheim Downgrades 2seventy bio to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Kelsey Goodwin has downgraded 2seventy bio (NASDAQ:TSVT) from Buy to Neutral.
September 13, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
2seventy bio has been downgraded from Buy to Neutral by Guggenheim.
The downgrade from Buy to Neutral by Guggenheim analyst Kelsey Goodwin indicates a less optimistic outlook for 2seventy bio. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100